title: FRS20064193FFP
design: DNA fragmentation was performed using a Covaris M220 Focused-ultrasonicator (Woburn, MA, USA), followed by end repair, phosphorylation, and adaptor ligation. Tissue samples were subjected to capture-based targeted sequencing using a panel consisting of 520 cancer-related genes (including whole exons of 310 genes and exons, introns, and promoter regions of the remaining 210 genes), spanning 1.7 Mb of human genome (OncoScreen Plus; Burning Rock Biotech, Guangzhou, China). DNA was hybridized with the capture probe baits, selected with magnetic beads, and PCR amplified. A bioanalyzer high-sensitivity DNA assay was then performed to assess the quality and size of the fragments and indexed samples were sequenced on a Nextseq500 sequencer (Illumina, Inc., San Diego, CA, USA) with paired-end reads.